Action CRNO B CERENO SCIENTIFIC AB (PUBL)
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Actions

CRNO B

SE0008241558

Cours en clôture NORDIC GROWTH MARKET
Autres places de cotation
 00:00:00 20/06/2023 		Varia. 5j. Varia. 1 janv.
0,521 SEK -7,13% Graphique intraday de Cereno Scientific AB (publ) +7,98% -76,90%
02/05 Cereno Scientific AB (Publ) annonce la nomination des membres du comité de nomination en vue de l'assemblée générale annuelle 2025 CI
16/04 Cereno Scientific AB (Publ) approuve l'élection de nouveaux administrateurs CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025
Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025
Report from Annual General Meeting 2024 of Cereno Scientific AB
Cereno Scientific AB Approves Election of New Directors
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014
Cereno Scientific Receives Patent Expansion in Europe
Cereno Scientific announces extended patent protection in Europe for CS585 program
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific
Cereno Scientific publishes Annual Report for 2023
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CRNO B
  4. Action CRNO B
  5. Actualités Cereno Scientific AB (publ)
  6. Autres langues